latest news releases from the newsroom
ATWEC Technologies, Inc
ATWEC Opens New Market
MEMPHIS, Tenn., Sept. 23, 2005 (PRIMEZONE) -- ATWEC Technologies, Inc. (Pink Sheets:ATWT) announced today that it has a contract with Penfield Children's Center and Hickman's Academy of Excellence of Milwaukee, WI to install its KiddieVoice(tm) Safety System on all their vehicles.
Limelight Media Group Inc
Limelight Media Group Expands Dynamic Media Work With Neiman Marcus
SEATTLE, Sept. 23, 2005 (PRIMEZONE) -- Limelight Media Group, Inc. (OTCBB:LMMG), an innovator in the content, creation and management of out-of-home digital advertising and information networks, announced today that it has expanded its portfolio of visual retail merchandising displays to include the Video Vitrine, a glass enclosed showcase for displaying fine wares that includes an elegant and eye-catching dynamic video running across the display base. Limelight subsidiary, IMPART, known for energizing the dynamic media industry with breakthrough innovations, worked closely with Neiman Marcus, who holds a patent on the design, to develop the new display. The Video Vitrine is being used with the company's other video mirror products to set Neiman Marcus apart in the world of retail by creating an exciting new experience for shoppers. The displays are currently deployed at Neiman Marcus stores in Florida, Nevada, and Texas with a roll out to additional stores currently in the works.
Integra LifeSciences Holdings Corp.
Integra Introduces Line Extension for Nerve Injury Products
PLAINSBORO, N.J., Sept. 23, 2005 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that Integra NeuroSciences has enhanced its product offering for the treatment of peripheral nerve injuries. Integra LifeSciences introduced a new 3 cm length of the NeuraGen(TM) Nerve Guide and a new 4 cm length of the NeuraWrap(TM) Nerve Protector this week at the American Society for Surgery of the Hand's 2005 Annual Meeting in San Antonio, Texas. Integra LifeSciences will also feature these new products at the Annual Meeting of the American Society of Plastic Surgeons in Chicago, Illinois next week. The new lengths allow Integra LifeSciences to address a larger portion of the market for peripheral nerve repair and protection, making possible the repair of gaps beyond the length of the gaps addressed by current NeuraGen (2 cm) and protection of compressed, scarred or partially injured nerves beyond the length of current NeuraWrap (2 cm). Integra will sell this product domestically through both its Integra NeuroSciences(TM) and Reconstructive Surgery sales forces.
OMX AB's Nomination Committee
STOCKHOLM, Sweden, Sept. 23, 2005 (PRIMEZONE) -- In accordance with a decision made at OMX's Annual General Meeting on April 7, 2005, a Nomination Committee is hereby announced. The Nomination Committee shall, among other things, develop a proposal for the composition of the Board of Directors, which will be presented for approval at the Annual General Meeting.
Volvo's Truck Plant in New River Valley Awarded Environmental Prize
GOTEBORG, Sweden, Sept. 23, 2005 (PRIMEZONE) -- The Volvo Group's truck plant in New River Valley, Virginia, in the U.S., has been awarded a local environmental prize for the intensive efforts made at the plant to reduce emissions. The prize -- the 2005 Governor's Environmental Excellence Award -- was awarded to the plant in recognition of a number of measures to improve the environment.
MorphoSys Announces Cross Licensing of Technologies with Lilly: AME Patent Dispute Settled
MARTINSRIED, Germany, Sept. 23, 2005 (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment:TecDAX) today announced a cross license agreement with Eli Lilly and Company on the use of certain recombinant protein technologies. Under the agreement, MorphoSys receives a license under the Kauffman patent estate to generate and screen certain recombinant peptide and protein libraries and to commercialize any resulting products. Financial terms were not disclosed. The agreement also provides Lilly access to the MorphoSys HuCAL GOLD(r) technology for Lilly's internal research and development programs. For any therapeutic antibodies Lilly develops under the agreement, it will pay MorphoSys exclusive licensing fees, success fees, milestone payments and royalties on end products. This agreement is part of a settlement to resolve patent litigation initiated by Applied Molecular Evolution (AME), a wholly owned subsidiary of Lilly, involving several U.S. patents of the Kauffman patent family.